J. Goldman & Co’s ADMA Biologics ADMA Stock Holding History

J. Goldman & Co’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,000	Closed	-$29K	–	360
2022 Q3	$29K	Hold	12,000	–	–	﹤0.01%	356
2022 Q2	$24K	Hold	12,000	–	–	﹤0.01%	329
2022 Q1	$22K	Hold	12,000	–	–	﹤0.01%	340
2021 Q4	$17K	Hold	12,000	–	–	﹤0.01%	337
2021 Q3	$14K	Hold	12,000	–	–	﹤0.01%	333
2021 Q2	$19K	Sell	12,000 -30,000	-71%	-$52.8K	﹤0.01%	386
2021 Q1	$74K	Sell	42,000 -334,319	-89%	-$765K	﹤0.01%	417
2020 Q4	$734K	Buy	+376,319	New	+$791K	0.04%	257
2016 Q3	–	Sell	-143,769	Closed	-$855K	–	301
2016 Q2	$855K	Buy	143,769 +22,793	+19%	+$160K	0.04%	266
2016 Q1	$979K	Sell	120,976 -780	-0.6%	-$4.46K	0.06%	225
2015 Q4	$983K	Hold	121,756	–	–	0.1%	179
2015 Q3	$1.02M	Sell	121,756 -1,100	-0.9%	-$10.2K	0.09%	171
2015 Q2	$1.14M	Buy	122,856 +1,556	+1%	+$13.5K	0.07%	182
2015 Q1	$1.19M	Buy	+121,300	New	+$1.22M	0.07%	215

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

J. Goldman & Co's ADMA Position: Q4 2022 in Review

J. Goldman & Co sold out of ADMA Biologics (ADMA) in Q4 2022, closing a stake of 12,000 shares — an estimated $29K sold.

J. Goldman & Co first reported a position in ADMA in Q1 2015 and held it in 14 quarters. The position peaked at $1.19M in Q1 2015. 159 funds tracked by Wall St. Rank hold ADMA as of Q4 2022.

J. Goldman & Co reported no remaining ADMA Biologics position as of Q4 2022 after selling out during the quarter.
J. Goldman & Co sold 12,000 ADMA Biologics shares in Q4 2022, an estimated $29K.
J. Goldman & Co first reported a position in ADMA Biologics in Q1 2015 and held it in 14 quarters.
J. Goldman & Co's ADMA Biologics position peaked at $1.19M in Q1 2015.
159 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.